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The angiogenesis is an important process in the pathogenesis of malignancies. It is regulated by various growth factors, with the vas-
cular endothelial growth factor (VEGF) playing the central role. The aim of the present study was to evaluate possible associations 
of functional VEGF −2578C>A, −634G>C, and +936C>T polymorphisms with the risk for occurrence and progression of non-small 
cell lung cancer (NSCLC) in patients living in Republic of Belarus. Materials and Methods: A total of 202 patients (147 males and 
55 females) diagnosed as having the NSCLC. The control group consisted of 336 individuals (245 males and 91 females) without 
an oncopathology. The total DNA was isolated from peripheral blood. We investigated the single nucleotide polymorphisms of VEGF 
(rs 2010963), (rs 699947), (rs 3025039). The genotyping was performed by PCR-RFLP analysis. Results: Our results revealed 
a marginally significant association of the –2578CC genotype (p=0.002) with a greater degree of tumor spread (Т2–Т4). Heterozy-
gous genotypes –2578СА and +936СT carriers were included into the follow-up group significantly more often (р=0.021 and р=0.012, 
respectively). Our study demonstrate that VEGF –2578A/C and +936C/T polymorphisms are among the factors determining the in-
dividual peculiarities of NSCLC course in this population and can be used for clarifying the prognosis of the disease.
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The angiogenesis is an important process in the pa-
t hogenesis of malignancies. It is regulated by various 
growth factors, with the vascular endothelial growth 
factor (VEGF-A or VEGF) playing the central role [1]. 
The VEGF gene expression is closely related to the de-
gree of vascularization and the prognosis for the oc-
currence of numerous solid tumors and is considered 
to be a predictor of resistance to the chemo- and ra-
diotherapy [2]. An elevated VEGF expression is associ-
ated with tumor growth and metastatic process, while 
the inhibited VEGF expression results in suppressed 
tumor growth [3].
The VEGF gene also triggers the activation of the pro-
tease cascade involved in the degradation of extracellular 
matrix, suppressing apoptosis, stimulates the endothelial 
cells survival, increases vascular permeability, inhibits 
the dendritic cells differentiation, regulates the hexose 
transport in endothelial cells as well as activates tissue 
factors and monocytes migration [1]. Clinical studies 
have shown that the high level of VEGF expression and, 
respectively, the increased number of microvessels 
in the tumor correlate with the disease stage and the un-
favorable prognosis for many tumor types, including 
the  non-small cell lung cancer (NSCLC) [4–8].
The VEGF gene is located on the short arm 
of chromosome 6 (6p21.3) and consists of eight 
exons and seven introns [7]. VEGF is a diametric 
glycoprotein, acting via tyrosine kinase receptors 
VEGFR1 and VEGFR2 located predominantly on en-
dothelial cells [9].
Polymorphic sites of VEGF gene determining the level 
of VEGF production are found in the promoter — 5´-un-
translated region (5´-UTR) as well as in 5´- and 3´-un-
translated regions of the gene (3´-UTR).
The VEGF gene polymorphism is associated with 
differentiated VEGF expression and protein produc-
tion. VEGF-2578C/C, −634 C/-genotypes are related 
to high level of VEGF expression [5, 9–12], while +936T 
allele correlates with low VEGF expression and its low 
levels in blood plasma [13, 14].
Recent studies show that individual polymorphic 
variants of VEGF influence the development of cer-
tain cancers. In particular, VEGF C-634G, C-2578A, 
C+936T polymorphisms are associated with an in-
creased lung cancer risk in Asian population [15]. Based 
on the above-mentioned, it can be assumed that these 
single nucleotide substitutions of the VEGF gene related 
to angiogenesis can affect the risk of tumour occur-
rence and progression as well as the patients’ survival.
The aim of the present study was to evaluate pos-
sible associations of functional VEGF −2578C>A, 
−634G>C, and +936C>T polymorphisms with the risk 
for occurrence and progression of NSCLC in patients 
living in the territory of the Republic of Belarus.
MATERIALS AND METHODS
202 patients (147 males and 55 females) diag-
nosed as having the NSCLC and treated at the Minsk 
City Oncology Dispensary during the period from 
2003 to 2012 were included in the study. The control 
group consisted of 336 individuals (245 males and 
91 females) without an oncopathology who were age-, 
gender- and comorbidity matched with NSCLC pa-
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tients. Clinical characteristics of patients with NSCLC 
and controls are presented in Table 1.
Table 1. Characteristics of study population
Characteristics
Patients with NSCLC
(n = 202)
Controls
(n = 336)
n (%) n (%)
Gender:
female 55 (27.2) 91 (27.1)
male 147 (72.8) 245 (72.9)
Smoking status:
smokes 67 (33.2) 201 (59.8)
does not smoke 119 (58.9) 135 (40.2)
no information 16 (7.9) −
Stage:
I 108 (53.5) −
II 27 (13.4) −
III 55 (27.2) −
IV 12 (5.9) −
Histology:
squamous-cell carcinoma 106 (52.5) −
adenocarcinoma 96 (47.5) −
Surgery:
lobectomy/bilobectomy 121 (65.1) −
pneumonectomy 42 (22.6) −
lung resection 13 (7.0) −
biopsy 10 (5.4) −
Therapy:
chemotherapy 65 (32.2) −
radiotherapy 39 (19.3) −
no therapy 98 (48.5) −
The study was performed in compliance with 
the principles of voluntary participation and confiden-
tiality, in accordance with the questioning of patients 
and the approval from the local Ethics Committee 
to study tissue samples and biological fluids.
The diagnosis of lung cancer in patients has been 
established on the basis of clinical signs of the disease, 
history data, bronchoscopy, X-ray examination and 
computed tomography, cytomorphology of sputum 
and tumour tissue biopsies. In the group of NSCLC 
patients, the mean age was 61.6±0.6, in the control 
group — 61.6±0.8 years.
All cases of lung malignancies have been identi-
fied according to the International Classification 
TNM/pTNM (7th edition, 2009). The histological 
type of lung carcinoma was determined according 
to the WHO histological criteria (3rd edition, 1999). 
The group of NSCLC included the most common 
neoplasms — squamous-cell carcinoma and ade-
nocarcinoma. The treatment was mostly surgical: 
lobectomy — 65.1%, pneumonectomy — 22.6%, 
lung resection — 7.0%. Only a biopsy was performed 
in 5.4% of cases, and in 7.9% of patients the operation 
was not done because of the process spread or severe 
comorbidity.
The total DNA from the peripheral blood was 
isolated using the Mathew method [16]. VEGF 
 C-634G (rs 2010963), C-2578A (rs 699947), C+936T 
(rs 3025039) polymorphisms were genotyped 
by the polymerase chain reaction method and the re-
striction fragment length polymorphism analysis (PCR-
RFLP analysis) using specific primers and restriction 
endonucleases [15, 17]. Primers for the analysis were 
synthesized by “Primetekh”, Minsk. The reagents for 
PCR and PCR-RFLP were manufactured by “Fermen-
tas”, Vilnius.
Statistical analysis. Statistical analyses were per-
formed using Excel and Statistica 7.0. When compa-
ring genotype frequencies, Pearson’s chi-squared test 
(χ2) was used. The association between the genotypes 
and the disease course was assessed by the value 
of odds ratio (OR).
RESULTS AND DISCUSSION
An elevated VEGF expression was revealed 
while studying the variety of malignancies: cancers 
of the colon, rectum, liver, lung, thyroid, digestive 
tract; breast, kidney and bladder adenocarcinoma; 
ovary and uterus carcinoma; angiosarcoma, multi-
form glioblastoma [18–21]. In turn, the level of VEGF 
expression depends largely on the polymorphic vari-
ants of the gene.
Therefore, the first phase of our work was to analy-
ses the association between VEGF C-634G, C-2578A 
and C+936T polymorphisms and the risk of NSCLC.
The analysis of data on VEGF genotyping in patients 
with NSCLC and controls is presented in Table 2.
Frequency distribution of alleles and genotypes 
of functionally significant VEGF polymorphisms 
in the population of patients living in the territory 
of the Republic of Belarus was close to the occur-
rence of the same polymorphisms in the control group. 
Statistically significant differences in the frequency 
of the studied genotypes between the group of pa-
tients with NSCLC and the control group were not 
39. Schultz A, Lavie L, Hochberg I, et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance 
for the development of the coronary artery collateral circulation. Circulation 1999; 100: 547–52.
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found. Similar results on the frequency of the studied 
VEGF single nucleotide substitutions were obtained for 
the populations in Germany and Sweden.
Based on the results, it can be assumed that there 
is no connection between the studied VEGF polymor-
phisms and the risk of NSCLC in this population.
Since VEGF is a major mediator of angiogenesis, 
it can be supposed that VEGF С-634G, C-2578A and 
C+936T polymorphisms will rather affect the pheno-
type and tumor biological behavior than the risk for 
tumor occurrence.
The next stage of our study was to find the relation-
ship between the polymorphisms under study and 
the clinical course of this disease. The comparative 
analysis of genotypes distribution of three functionally 
significant VEGF polymorphisms and tumor size, me-
tastasis and clinical outcomes in the group of patients 
with NSCLC has been carried out.
VEGF triggers the neoplastic angiogenesis,  resulting 
in increased microvascular density, and malignant tis-
sue receives more nutrients [23, 24]. VEGF secretion 
by tumor cells leads to the synthesis of proangiogenic 
factors. The newly formed vessels begin to supply 
malignant tissue with oxygen and nutrients; the tumor 
is growing and producing more VEGF. VEGF increases 
the level of VEGFR2 receptor expression by endothe-
liocytes of tumor microvessels, thus stimulating the cell 
growth and endothelial cells proliferation [25].
Structurally and functionally the neoplastic vessels 
differ from the normal ones, with high permeability, 
chaotic branching, multiple loops, weaves, dead-end 
branches, lack of structured vasculature being typical 
for them [2]. Chaotic arrangement of tumor vessels 
results in uneven oxygen supply to the surrounding 
tissues, formation of local hypoxic foci, and is followed 
by tumor resistance to the radio-and chemotherapy.
With an elevated VEGF expression, the vascular 
permeability increases leading to a higher interstitial 
and intratumoural pressure, facilitating the penetration 
of tumor cells into the bloodstream [26].
The relationship between the tumor angiogenesis 
level, tumor size and metastatic process is confirmed 
by the correlation between the course of the disease 
and microvascular density of the primary tumor [27–
32]. Different VEGF polymorphisms are associated 
with lymphogenic and hematogenous metastases 
in a variety of malignancies [28, 29].
The performed analysis of the relationships be-
tween three VEGF gene polymorphisms and tumor size 
(Table 3) has shown that genotype –2578СС carriers 
displayed a greater degree of tumor spread (Т2–4) sig-
nificantly more frequently (р = 0,002) compared to the 
primary focus spread (Т1). On the contrary, the carri-
ers of –2578СА genotype more often presented with 
small non-invasive cancer (Т1). However, in this group 
of NSCLC patients, no statistically significant associa-
tions between the studied polymorphic allele variants 
and regional and/or distant metastases were found 
(Table 4).
The in vitro studies conducted by M. Moham-
madi and M.С. Shahbazi has shown that -2578C allele 
correlated with higher VEGF expression compared 
to A allele [30, 31]. Similar results were obtained 
by M. Perrot-Applanat who proved that –2578С allele 
was associated with an elevated VEGF expression and 
pointed to the possible involvement of VEGF proteins 
in the autocrine regulation of the tumor growth [32]. 
Perhaps, this is likely to explain our findings, where 
the homozygous carriers (–2578СС) had higher degree 
of the tumor spread. The lower level of VEGF expres-
sion in the presence of –2578А allele seems to have 
a protective effect in heterozygous carriers (–2578СА) 
associated with a lesser degree of the neoplasm spread.
In the population under study, a significant rela-
tionship between the –2578СА variant and the degree 
of spread of the primary tumor as well as the outcome 
of the disease was detected (Table 5). Heterozy-
Table 2. Frequency distribution of polymorphic variants of VEGF in patients with NSCLC and control groups in different populations
Genotype Belarus (original data) Germany [22] Sweden [22]Patients Controls OR (95% CI) Patients Controls OR (95% CI) Patients Controls OR (95% CI)VEGF (G634C) N=186; n (%) N=364; n (%) N, % N, % N=936; n (%) N=941; n (%)
GG 83 (44.6) 186 (51.1) 0.77 (0.54–1.10) − − − 488 (52.1) 492 (52.3) 1.00
GC 88 (47.3) 154 (42.3) 1.22 (0.86–1.75) − − − 363 (38.8) 367 (39.0) 1.00 (0.82–1.21)
CC 15 (8.1) 24 (6.6) 1.24 (0.64–2.43) − − − 85 (9.1) 82 (8.7) 1.05 (0.74–1.47)
G allele 254 (68.3) 526 (72.3) 0.83 (0.63–1.09) − − − 1339 (71.5) 1351 (72.0) 0.99 (0.86–1.14)
С allele 118 (31.8) 202 (27.7) 1.21 (0.92–1.59) − − − 533 (28.5) 531 (28.0) 1.01 (0.86–1.17)
VEGF (С2578А) N=162; n (%) N=360; n (%) N=153; n (%) N=162; n (%) N=939; n (%) N=940; n (%)
СС 41 (25.3) 83 (23.0) 1.13 (0.74–1.74) 44 (28.8) 50 (30.9) 1.00 258 (27.5) 257 (27.3) 1.00
СА 90 (55.6) 186 (51.7) 1.17 (0.81–1.70) 75 (49.0) 72 (44.4) 1.18 (0.68–2.06) 449 (47.8) 451 (48.0) 0.99 (0.79–1.24)
АА 31 (19.1) 91 (25.3) 0.70 (0.44–1.11) 34 (22.2) 40 (24.7) 0.97 (0.50–1.86) 232 (24.7) 232 (24.7) 1.00 (0.82–1.23)
C allele 172 (53.1) 352 (48.9) 1.18 (0.91–1.54) 163 (53.3) 172 (53.1) 1.01 (0.74–1.38) 965 (51.4) 965 (51.2) 0.78 (0.68–0.89)
A allele 152 (46.9) 368 (51.1) 0.85 (0.65–1.10) 143 (46.7) 152 (46.9) 0.99 (0.73–1.36) 913 (48.6) 915 (48.8) 1.05 (0.93–1.20)
VEGF (С936T) N=161; n (%) N=360; n (%) N=153; n (%) N=163; n (%) N=924; n (%) N=934; n (%)
CC 115 (71.4) 267 (74.2) 0.87 (0.57–1.32) 120 (78.4) 128 (78.5) 1.00 708 (76.6) 720 (77.1) 1.00
CT 38 (23.6) 80 (22.2) 1.08 (0.70–1.68) 31 (20.3) 31 (19.0) 1.07 (0.59–0.93) 204 (22.1) 203 (21.7) 1.02 (0.81–1.28)
TT 8 (5.0) 13 (3.6) 1.40 (0.57–3.44) 2 (1.3) 4 (2.5) 0.53 (0.07–3.46) 12 (1.3) 11 (1.2) 1.11 (0.45–2.71)
С allele 268 (83.2) 614 (85.3) 0.86 (0.60–1.23) 271 (59.8) 287 (88.0) 0.20 (0.14–0.30) 1620 (87.7) 1643 (88.0) 0.97 (0.80–1.18)
T allele 54 (16.8) 106 (14.7) 1.17 (0.82–1.67) 182 (40.2) 39 (12.0) 4.94 (3.37–7.25) 228 (12.3) 225 (12.0) 1.03 (0.84–1.25)
Table 3. Distribution of frequencies of polymorphic variants of VEGF and tumor size in patients with NSCLC
Tumour 
size N
G634C
N
C2578A
N
C936T
GG GC CC CC CA AA CC CT TT
n % n % n % n % n % n % n % n % n %
T1 70 32 45.7 33 47.1 5 7.1 57 6 10.5* 40 70.2** 11 19.3 41 29 70.7 11 26.8 1 2.4
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gous genotype –2578СА carriers were included into 
the follow-up group significantly more often (р = 0.021). 
It should be noted that a similar results was observed 
for another VEGF polymorphism — the heterozygous 
variant +936СT located in the 3´-UTR (р = 0.012). More-
over, C. Oliveira et al. have shown that heterozygous 
+936СT genotype was increasingly associated with 
a non-recurrent disease [11]. No associations between 
the VEGF –634G>C polymorphism and the survival 
of patients with NSCLC have been found.
It has been demonstrated that the polymorphism 
of a single nucleotide located in the promoter region 
or 3´- and 5´-UTR affects the protein expression 
at the transcriptional level [33]. Initially, the hypoxia 
induced factor (HIF-1) joins VEGF gene in the pro-
moter region (–2578СА polymorphism) and increases 
its expression. Gene polymorphism in this region can 
weaken or strengthen this interaction, and, therefore, 
alter the VEGF expression (–2578СА) [34] that, in turn, 
will affect the formation and permeability of microves-
sels and, finally, the tumor size, metastasis and survival.
Based on the results of the study on the correla-
tion between the polymorphisms and development 
of the di sease in this population, it has been estab-
lished that the carriers of –2578СС genotype displayed 
a greater degree of tumor spread (Т2–4) significantly 
more often (р = 0.002) while the carriers of –2578СА 
genotype presented with small non-invasive can-
cers (Т1) more frequently (р = 0.021). The carriers of 
–2578C/A genotype were significantly often observed 
(р = 0.021) in the “follow-up” group. Given that the high 
level of VEGF expression is related to an increased risk 
of a recurrent disease and shorter survival of subjects 
with different cancers [35], one may suggest the VEGF 
(–2578С/-) genotype to contribute to the high expression 
of the corresponding protein product in the development 
of NSCLC.
The mechanism of most associations between single 
nucleotide substitutions and clinical behavior of tumors 
is still largely unclear. It should be taken into account 
that 5´- and 3´-UTR contain key regulatory elements 
sensitive to hypoxia [36–38] and contribute to high 
variability of VEGF production [39]. For instance, VEGF-
634G>C and –2578A>C polymorphisms in the 5´-UTR 
affect the efficiency of protein translation [33], and 
936C>T polymorphism in the 3´-UTR influences the VEGF 
circulating plasma concentrations [13] and tumor tissue 
expression of VEGF [5]. This can explain the protective ef-
fect of the VEGF +936T allele in breast cancer metastasis 
(due to the reduced VEGF expression) [4, 11].
Thus, the results of our study demonstrate that 
VEGF –2578A/C and +936C/T polymorphisms are 
among the factors determining the individual pecu-
liarities of NSCLC course in this population and can 
be used for clarifying the prognosis of the disease.
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